Moberg Pharma AB's total inventories for the quarter that ended in Mar. 2026 was €0.54 Mil. Moberg Pharma AB's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €0.43 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Moberg Pharma AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €0.42.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Moberg Pharma AB's Days Inventory for the
three
months ended in Mar. 2026 was 254.91.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Moberg Pharma AB's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.36.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Moberg Pharma AB's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.95.
Moberg Pharma AB (FRA:MB8) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Moberg Pharma AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Moberg Pharma AB's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Moberg Pharma AB Total Inventories Related Terms
Moberg Pharma AB Total Inventories Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Moberg Pharma AB (FRA:MB8) has a Total Inventories of €0.54 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Total Inventories too high?
Moberg Pharma AB's current Total Inventories is €0.54 Mil. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Total Inventories compare to ZTS?
Moberg Pharma AB's Total Inventories of €0.54 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Moberg Pharma AB and its competitors. Moberg Pharma AB's current Total Inventories is €0.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Total Inventories of €0.54 Mil. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current Total Inventories is €0.54 Mil. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Total Inventories is €0.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.
Key valuation signals for FRA:MB8:
Total Inventories: €0.54 Mil
GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
